Muscle cyclo-oxygenase-2 pathway contributes to the exaggerated muscle mechanoreflex in rats with congestive heart

Ariel Morales1, Wei Gao, Jian Lu

  • 1Heart & Vascular Institute, The Pennsylvania State University College of Medicine, Hershey, PA, USA.

Insights

Heart failure (HF) exacerbates the muscle mechanoreflex, a response involving cyclo-oxygenase-2 (COX-2). Inhibiting COX-2, but not COX-1, in rats with HF significantly reduced this augmented reflex, indicating COX-2

Area of Science:

  • Cardiovascular Physiology
  • Skeletal Muscle Reflexes
  • Enzyme Function and Regulation

Background:

  • Cyclo-oxygenase (COX) enzymes produce prostaglandins, influencing sympathetic nerve activity and blood pressure during muscle contraction.
  • The exercise pressor reflex, activated by static muscle contraction, increases sympathetic nerve activity and blood pressure.
  • COX products can exaggerate the exercise pressor reflex in heart failure (HF), primarily through muscle mechanoreflex overactivity.

Purpose of the Study:

  • To investigate the contribution of cyclo-oxygenase-1 (COX-1) and cyclo-oxygenase-2 (COX-2) pathways to augmented muscle mechanoreflex activity in heart failure (HF).
  • To determine if COX-2 is overexpressed in skeletal muscle of rats with HF.
  • To assess the effect of COX-1 and COX-2 inhibition on the muscle mechanoreflex in HF.

Main Methods:

  • Western blot analysis to compare COX-1 and COX-2 protein expression in hindlimb skeletal muscle of control rats and rats with experimentally induced HF.
  • Evoking the muscle mechanoreflex via passive tendon stretch in rats.
  • Administering selective COX-1 (FR-122047) and COX-2 (SC-236) inhibitors via arterial injection to assess their impact on reflex sympathetic and pressor responses.

Main Results:

  • Skeletal muscle COX-2 expression was significantly upregulated in rats with HF compared to controls.
  • COX-1 expression showed no significant difference between HF and control rats.
  • Selective inhibition of COX-2 with SC-236 significantly attenuated the exaggerated muscle mechanoreflex (renal sympathetic nerve activity and mean arterial pressure) in rats with HF.
  • Inhibition of COX-1 with FR-122047 did not significantly alter the mechanoreflex responses in rats with HF.

Conclusions:

  • Heightened expression of COX-2 within hindlimb muscles contributes to the exaggerated muscle mechanoreflex observed in congestive heart failure (HF).
  • Targeting the COX-2 pathway may represent a therapeutic strategy for modulating aberrant muscle reflex activity in HF patients.

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Nitric Oxide Signaling Pathway01:28

Nitric Oxide Signaling Pathway

Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure to...
Pathophysiology of Cardiac Performance01:29

Pathophysiology of Cardiac Performance

Typical heart performance is influenced by heart rate, rhythm, myocardial contraction, and metabolism or blood flow. The cardiac muscle exhibits distinct electrophysiological features, including pacemaker activity and calcium channel control, which play a vital role in the heart's response to various drugs. The autonomic nervous system, comprising the sympathetic and parasympathetic branches, regulates heart rate. Sympathetic activation increases heart rate, while parasympathetic activation...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...